---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-027743"
form_type: "8-K"
ticker: "BOLT"
cik: "0001641281"
company_name: "Bolt Biotherapeutics, Inc."
filed_at: "2023-06-13T23:59:59+00:00"
generated_at: "2026-06-14T02:06:45.376728+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Bolt Biotherapeutics annual meeting elects three directors, ratifies PwC as auditor

## Summary
- Randall C. Schatzman, Ph.D. elected with 18,339,155 votes for, 49,830 withheld.
- Edgar G. Engleman, M.D. elected with 18,300,413 votes for, 88,572 withheld.
- James I. Healy, M.D., Ph.D. elected with 14,449,941 votes for, 3,939,044 withheld.
- Ratification of PricewaterhouseCoopers LLP as auditor for FY2023: 26,831,426 for, 33,439 against, 15,578 abstain.

## SEC filing metadata
- accession: 0000950170-23-027743
- form_type: 8-K
- ticker: BOLT
- cik: 0001641281
- company_name: Bolt Biotherapeutics, Inc.
- filed_at: 2023-06-13T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641281/000095017023027743/0000950170-23-027743-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641281/000095017023027743/bolt-20230612.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-027743
- JSON: https://secwatch.observer/filing/0000950170-23-027743.json
- Plain text: https://secwatch.observer/filing/0000950170-23-027743.txt

## Key facts
- Shareholder Votes
  Bolt Biotherapeutics, Inc. shareholders approved Election of Class II directors at the 2023-06-12 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-12
  source text: The following director nominees were elected to serve as Class II members of the Company’s board of directors until the Company’s 2026 Annual Meeting of Stockholders, or until their respective successor is duly elected and qualified, or until their respective death, resignation or removal: Nominee Votes For Votes Withheld Broker Non-Votes Randall C. Schatzman, Ph.D. 18,339,155 49,830 8,491,458 Edgar G. Engleman, M.D. 18,300,413 88,572 8,491,458 James I. Healy, M.D., Ph.D. 14,449,941 3,939,044 8,491,458
  evidence_url: https://www.sec.gov/Archives/edgar/data/1641281/000095017023027743/0000950170-23-027743-index.htm
- Shareholder Votes
  Bolt Biotherapeutics, Inc. shareholders approved Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm at the 2023-06-12 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-12
  source text: The selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was ratified. Votes For Votes Against Votes Abstaining 26,831,426 33,439 15,578
  evidence_url: https://www.sec.gov/Archives/edgar/data/1641281/000095017023027743/0000950170-23-027743-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.